Displaying drugs 6001 - 6025 of 8235 in total
Sepiapterin
Sepiapterin is under investigation in clinical trial NCT03519711 (A Study of CNSA-001 in Primary Tetrahydrobiopterin (BH4) Deficient Participants With Hyperphenylalaninemia).
Investigational
Matched Description: … Sepiapterin is under investigation in clinical trial NCT03519711 (A Study of CNSA-001 in Primary Tetrahydrobiopterin …
Cobolimab
Cobolimab is under investigation in clinical trial NCT04655976 (Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants).
Investigational
Matched Description: … Cobolimab is under investigation in clinical trial NCT04655976 (Study of Cobolimab in Combination With …
Mibavademab
Mibavademab is under investigation in clinical trial NCT04159415 (Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy).
Investigational
Matched Description: … Mibavademab is under investigation in clinical trial NCT04159415 (Study of REGN4461, a Leptin Receptor …
QR-313
QR-313 is an antisense oligonucleotide targeting exon 73. It is being investigated for the treatment of dystrophic epidermolysis bullosa.
Investigational
Matched Description: … It is being investigated for the treatment of dystrophic epidermolysis bullosa.[A259867] …
HRS-1167
HRS-1167 is under investigation in clinical trial NCT05473624 (Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors).
Investigational
Matched Description: … HRS-1167 is under investigation in clinical trial NCT05473624 (Study of HRS-1167 as Monotherapy in Patients …
Divozilimab
Divozilimab is under investigation in clinical trial NCT05730699 (Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)).
Investigational
Matched Description: … Divozilimab is under investigation in clinical trial NCT05730699 (Efficacy and Safety of Divozilimab …
Acasunlimab
Acasunlimab is under investigation in clinical trial NCT06046274 (GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer).
Investigational
Matched Description: … investigation in clinical trial NCT06046274 (GEN1046 in Combination With Anticancer Agents for the Treatment of …
Petosemtamab
Petosemtamab is under investigation in clinical trial NCT03526835 (A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors).
Investigational
Matched Description: … Petosemtamab is under investigation in clinical trial NCT03526835 (A Study of Bispecific Antibody MCLA …
Pegtarviliase
Pegtarviliase is under investigation in clinical trial NCT05154890 (A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS Deficiency).
Investigational
Matched Description: … Pegtarviliase is under investigation in clinical trial NCT05154890 (A Multiple Ascending Dose Study of …
Mivelsiran
Mivelsiran is under investigation in clinical trial NCT06393712 (A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy).
Investigational
Matched Description: … Mivelsiran is under investigation in clinical trial NCT06393712 (A Phase 2 Trial of ALN-APP in Patients …
Lazuvapagon
Lazuvapagon is under investigation in clinical trial NCT03116191 (Trial of SK-1404 for Nocturia Due to Nocturnal Polyuria in Japanese Subjects).
Investigational
Matched Description: … Lazuvapagon is under investigation in clinical trial NCT03116191 (Trial of SK-1404 for Nocturia Due to …
Pegozafermin
Pegozafermin is under investigation in clinical trial NCT05852431 (To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia).
Investigational
Matched Description: … Pegozafermin is under investigation in clinical trial NCT05852431 (To Evaluate the Efficacy and Safety of …
Danburstotug
Danburstotug is under investigation in clinical trial NCT04809012 (Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors).
Investigational
Matched Description: … Danburstotug is under investigation in clinical trial NCT04809012 (Study of STI-3031 in Patients With …
TAS-102
TAS-102 (Taiho Pharma USA, Inc.) is an anti-cancer drug under development and in stage 3 clinical trials for the treatment of colorectal cancer. It is composed of the thymidine phosphorylase inhibitor (TPI) tipiracil and the cytotoxin trifluridine. Trifluridine inhibits tumor growth by being incorporated into DNA during DNA synthesis. Tipiracil...
Investigational
Matched Description: … USA, Inc.) is an anti-cancer drug under development and in stage 3 clinical trials for the treatment of ... It is composed of the thymidine phosphorylase inhibitor (TPI) tipiracil and the cytotoxin trifluridine …
Malacidin A
Malacidin A, along with DB14052, is a member of a class of chemicals made by bacteria found in soil that can kill Gram-positive bacteria . Malacidins are 10-member macrocycle lipopeptides discovered via gene sequencing and bioinformatic analysis. While structurally similar to other macrocycle drugs like DB00080 and DB06087, Malacidin A...
Experimental
Matched Description: … Malacidin A, along with [DB14052], is a member of a class of chemicals made by bacteria found in soil …
Malacidin B
Malacidin B, along with DB14051, is a member of a class of chemicals made by bacteria found in soil that can kill Gram-positive bacteria . Malacidins are 10-member macrocycle lipopeptides discovered via gene sequencing and bioinformatic analysis. While structurally similar to other macrocycle drugs like DB00080 and DB06087, Malacidin B...
Experimental
Matched Description: … Malacidin B, along with [DB14051], is a member of a class of chemicals made by bacteria found in soil …
Valinomycin
A cyclododecadepsipeptide ionophore antibiotic produced by Streptomyces fulvissimus and related to the enniatins. It is composed of 3 moles each of L-valine, D-alpha-hydroxyisovaleric acid, D-valine, and L-lactic acid linked alternately to form a 36-membered ring. (From Merck Index, 11th ed) Valinomycin is a potassium selective ionophore and is commonly used...
Experimental
Matched Description: … It is composed of 3 moles each of L-valine, D-alpha-hydroxyisovaleric acid, D-valine, and L-lactic acid …
CVnCoV
The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body. As of June 2020, the company received regulatory approval from German and Belgian Authorities...
Investigational
Matched Description: … Phase 1 clinical trials of this vaccine (NCT04449276). ... As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence …
V1003
V1003 is an intranasal formulation of buprenorphine, an opiate analgesic, for the management of post-operative pain in hospital and home settings. Buprenorphine is a well-known analgesic and the intranasal formulation has the potential to provide a convenient alternative to other treatments, allowing patients to manage their post-operative pain both prior...
Investigational
Matched Description: … V1003 is an intranasal formulation of buprenorphine, an opiate analgesic, for the management of post-operative …
Icotinib
Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc. was given a “May Proceed” from the US FDA to conduct a Phase I study for the...
Experimental
Investigational
Matched Description: … icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC). ... Pharma, Inc. was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of …
Platinum
Platinum is under investigation for the treatment of Metastatic Breast Cancer, Non-small Cell Lung Cancer, Gastric Large Cell Neuroendocrine Carcinoma, Colorectal Large Cell Neuroendocrine Carcinoma, and Pancreatic Large Cell Neuroendocrine Carcinoma, among others. Platinum has been investigated for the treatment and supportive care of Ovarian Cancer, Fallopian Tube Cancer, Peritoneal...
Investigational
Matched Description: … Platinum is under investigation for the treatment of Metastatic Breast Cancer, Non-small Cell Lung Cancer ... Platinum has been investigated for the treatment and supportive care of Ovarian Cancer, Fallopian Tube …
LV-SMENP Vaccine
LV-SMENP-DC is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises dendritic cells that are modified with lentiviral vector-expressing synthetic minigene which are based on domains of selected viral proteins. This vaccine is also administered with antigen-specific cytotoxic T lymphocytes (CTLs).
As of August 2020, this vaccine...
Investigational
Matched Description: … cells that are modified with lentiviral vector-expressing synthetic minigene which are based on domains of ... As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials …
Prostaglandin D2
The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects.
Investigational
Matched Description: … The principal cyclooxygenase metabolite of arachidonic acid. ... It is released upon activation of mast cells and is also synthesized by alveolar macrophages. …
Dibromothymoquinone
At low concentrations, this compound inhibits reduction of conventional hydrophilic electron acceptors, probably acting as a plastoquinone antagonist. At higher concentrations, it acts as an electron acceptor, intercepting electrons either before or at the site of its inhibitory activity. [PubChem]
Experimental
Matched Description: … At low concentrations, this compound inhibits reduction of conventional hydrophilic electron acceptors ... concentrations, it acts as an electron acceptor, intercepting electrons either before or at the site of …
BF-37
BF-37 for the treatment of atopic dermatitis and/or psoriasis. The active ingredient in BF-37 is Riluzole, applied in a topical formulation, which is believed to correct the imbalances of the immune system that cause atopic dermatitis or psoriasis.
Investigational
Matched Description: … BF-37 for the treatment of atopic dermatitis and/or psoriasis. ... in BF-37 is Riluzole, applied in a topical formulation, which is believed to correct the imbalances of …
Displaying drugs 6001 - 6025 of 8235 in total